Ningmitai Capsule Facilitates Residual Fragment Clearance after Ureteroscopic Holmium Laser Lithotripsy: A Multicenter Randomized Controlled Trial
Urologia Internationalis · 2025
DOI: 10.1159/000548511 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Urologia Internationalis, 2025. Verfasst von Wei Xiang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Wuhan No. 1 Hospital, Wuhan, China. Hauptthemen laut MEDLINE: Lithotripsy, Laser, Ureteroscopy, Ureteral Calculi, Lasers, Solid-State. Die Arbeit nennt 21 Literaturangaben.
Abstract (Originalsprache)
Introduction
The aim of the study was to evaluate the efficacy of Ningmitai capsule (NMT), a traditional Chinese medicine, alone or combined with tamsulosin, in promoting residual stone fragment clearance after ureteroscopic holmium laser lithotripsy (Ho:YAG-URS).
Methods
In this multicenter, prospective, randomized controlled trial, 222 patients with distal ureteral residual fragments (3.18 ± 1.14 mm) post-Ho:YAG-URS were randomly assigned to three groups: control (no medication), NMT (0.38 g × 4 capsules, 3 times/day), or NMT + tamsulosin (0.4 mg/day). Primary outcome was the stone-free rate (SFR) at 4 weeks. Secondary outcomes included stone expulsion rate, stone-free time, and expulsion time.
Results
At 4 weeks, SFRs were 76.19% (control), 92.21% (NMT; p = 0.023 vs. control), and 98.91% (combination; p < 0.001 vs. control). The combination group achieved significantly shorter stone-free time (6.37 ± 2.25 vs. 15.82 ± 21.62 days, p < 0.0001) and expulsion time (2.27 ± 1.17 vs. 6.64 ± 10.56 days, p < 0.0001) compared to the control group. No drug-related adverse events were reported.
Conclusions
NMT significantly accelerates residual fragment expulsion post-Ho:YAG-URS, with synergistic effects observed when combined with tamsulosin. This study demonstrates that patients can benefit from NMTs alone or combined with tamsulosin, particularly for small fragments where alpha-blockers show limited efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Wuhan No. 1 Hospital, Wuhan, China.
- Department of Urology, Wuhan Central Hospital, Wuhan, China.
- Department of Urology, Wuhan Fourth Hospital, Wuhan, China.
- Department of Urology, Wuhan Third Hospital, Wuhan, China.
- Department of Urology, Wuhan No. 1 Hospital, Wuhan, China, 739445573@qq.com.
Zitieren
APA
Xiang, W., Zhang, C., Guo, Y., Zheng, T., Zhang, J., & Yuan, J. (2025). Ningmitai Capsule Facilitates Residual Fragment Clearance after Ureteroscopic Holmium Laser Lithotripsy: A Multicenter Randomized Controlled Trial. Urologia Internationalis. https://doi.org/10.1159/000548511
Vancouver
Xiang W, Zhang C, Guo Y, Zheng T, Zhang J, Yuan J. Ningmitai Capsule Facilitates Residual Fragment Clearance after Ureteroscopic Holmium Laser Lithotripsy: A Multicenter Randomized Controlled Trial. Urologia Internationalis. 2025. doi:10.1159/000548511
BibTeX
@article{Xiang2025,
author = {Xiang, Wei and Zhang, Chuanhua and Guo, Yonglian and Zheng, Tao and Zhang, Jingyu and Yuan, Jingdong},
title = {Ningmitai Capsule Facilitates Residual Fragment Clearance after Ureteroscopic Holmium Laser Lithotripsy: A Multicenter Randomized Controlled Trial},
journal = {Urologia Internationalis},
year = {2025},
doi = {10.1159/000548511}
}
EUVIMED